Unexpected EU delay for J&J/Basilea's new antibiotic Zevtera
This article was originally published in Scrip
Executive Summary
Johnson & Johnson/ Basilea's new antibiotic Zevtera (ceftobiprole medocaril) faces an unexpected delay in reaching the EU marketplace after the CHMP decided to delay the European Commission decision process pending completion of a good clinical practice inspection, despite issuing a positive opinion for the product in November.